Cancer Council Victoria | Victorian Cancer Trials Link

A Phase 1/2 Study of CLIO-8221 in Patients With Advanced Solid Tumors

Clinical summary

This is a study of a medicine called CLIO-8221 in people with advanced solid cancers. You may be eligible if you have a solid tumour that is metastatic or unable to be removed with surgery (unresectable) that is not suitable for further local treatment, and have received other available treatments they are eligible for.

This study will be carried out in two parts (called phases).
Phase 1In the first part of the study, the goal is to find a safe dose of the study medicine (CLIO□8221). Small groups of participants will receive different dose levels. Researchers will carefully monitor side effects to find the highest dose that people can safely tolerate, or the dose that is best to use in later parts of the study.
Phase 2In the second part, the study will focus on specific types of cancer. Participants will receive CLIO□8221at the selected dose to further refine the dose and to see how well the treatment works against different tumours. This phase helps researchers understand the potential benefits of the treatment.

Conditions

This trial is treating patients with advanced, metastatic or unresectable solid tumours

Trial Acronym
Callio CLIO-8221

Trial Identifiers
NCT07300943
CLIO-8221-001

Cancer
Adenoid cystic carcinoma, Adrenocortical carcinoma, Anus, Appendix, Astrocytoma, Basal cell carcinoma, Bile duct (Cholangiocarcinoma), Bladder, Bone, Brain, Brain stem, Breast, Cancer of Unknown Primary, Central Nervous System, Cervix, Chondrosarcoma, Colon, Colorectum (Bowel), Cutaneous Squamous Cell Carcinoma (CSCC), Endometrium, Ependymomas, Epithelial, Ewing's Sarcoma, Fallopian tube, Gallbladder, Gastrointestinal stromal tumors (GISTs), Gastro-oesophageal junction , Germ cell and sex cord stromal cell, Germ cell tumour, Glioblastoma (GBM) , Glioma, Head and neck, Kaposi Sarcoma, Kidney, Leiomyosarcoma, Liposarcoma, Liver, Lung, Medullablastoma, Melanoma (Ocular), Melanoma (Skin), Meningioma, Merkel cell, Mesothelioma, Neuroblastoma, Neuroendocrine tumours, Non-Small Cell Lung Cancer, Nose (nasopharynx), Oesophagus, Oral cavity, Oropharynx, Osteosarcoma, Ovary, Pancreas, Penis, Peritoneal, Prostate, Rectum, Renal cell carcinoma, Retinoblastoma, Rhabdomyosarcoma, Salivary glands, Sarcoma, Small bowel (small intestine) cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma, Spinal Cord, Squamous cell carcinoma (Head and Neck), Squamous cell carcinoma (Skin), Stomach (Gastric), Stromal Sarcoma, Synovial Sarcoma, Testis, Throat (hypopharynx), Thyroid, Urinary tract, Urothelial, Uterus, Vagina, Voice box (larynx), Vulva, Wilm's tumour

Age: 18+
Phase: I/II

For full trial details, visit trials.cancervic.org.au/details/vctl_nct07300943